Discovering the role of legumain in the pathogenesis of various diseases, as discussed above, has initiated an approach of targeting legumain or utilizing legumain for prodrug activation, which may provide novel therapeutic opportunities for, e.g., cancer therapy [152,153]. This evidence concerns the gene LGMN and cancer.